BTIG Downgrades Aardvark Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 90.4%

Neg 90.4% Neu 0% Pos 0%

BTIG analyst Jeet Mukherjee downgrades Aardvark Therapeutics (NASDAQ:AARD) from Buy to Neutral.

Comments

No comments yet. Be the first!